New combo therapy offers hope for hard-to-treat rectal cancer
NCT ID NCT06767007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining targeted radiation (SBRT) with an immunotherapy drug (PD-1 antibody) can help people whose rectal cancer has returned and cannot be surgically removed. About 31 adults with a specific type of colorectal cancer will receive the treatment and be followed for at least 2 years. The goal is to see if this approach improves survival and is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE LOCALLY RECURRENT RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510065, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.